{"id":70,"date":"2014-05-05T12:33:54","date_gmt":"2014-05-05T10:33:54","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=70"},"modified":"2014-05-13T10:58:06","modified_gmt":"2014-05-13T08:58:06","slug":"pfizer-utile-i-trim-15-a-233-mld-fatturato-85-pesano-divisioni-chiave","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/pfizer-utile-i-trim-15-a-233-mld-fatturato-85-pesano-divisioni-chiave\/","title":{"rendered":"Pfizer: I quarter profit. -15% to \u20ac2.33bn $, turnover -8.5%, key divisions weigh"},"content":{"rendered":"<p>(Il Sole 24 Ore Radiocor) \u2013 New York, May 05 \u2013 In the first three months of the year, Pfizer saw its 15% profits fall, in the wake of the drop in turnover in two key divisions, the pharmaceutical one (-13% to 5.99 billion dollars) and innovation (-7% to 3.08 billion dollars). The pharmaceutical giant posted earnings of $2.33 billion, 36 cents a share, versus $2.75 billion, 38 cents a share, in the same period last year. Excluding special items, profits rose 51 cents a share to 57 cents. Turnover dropped by 8.5% to 11.35 billion dollars, excluding extraordinary charges -9% to 11.3 billion. Analysts were expecting profits of 55 cents a share on $12.08 billion in business.<\/p>","protected":false},"excerpt":{"rendered":"<p>(Il Sole 24 Ore Radiocor) &#8211; New York, 05 mag &#8211; Nei primi tre mesi dell&#8217;anno Pfizer ha visto calare i profitti del 15%, sulla scia del ribasso del fatturato in due divisioni chiave, quella farmaceutica (-13% a 5,99 miliardi di dollari) e innovazione (-7% a 3,08 miliardi di dollari). Il colosso farmaceutico ha messo &hellip;<\/p>","protected":false},"author":1,"featured_media":71,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15,16],"tags":[],"class_list":["post-70","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-primo-piano"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/70","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=70"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/70\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/71"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=70"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=70"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=70"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}